Abstract:Tumor radioresistance, or the lack of control of certain tumors with this treatment, can result in locoregional recurrence; therefore, there is great interest in understanding the underlying biology and developing strategies to overcome this problem. MicroRNAs (miRNAs, miRs) are small non‐coding RNAs that regulate gene expression at the post‐transcriptional level and participate in cancer invasion, progression, metastasis, and therapeutic resistance. Emerging evidence indicates that miRNAs play a critical role in modulating key cellular pathways that mediate response to radiation, influencing radiosensitivity of cancer cells through interaction with other biological processes such as cell cycle checkpoints, apoptosis, autophagy, epithelialmesenchymal transition, and cancer stem cells. Today, most studies on patient data report different, results on the miRNAs evaluated for each tumor type, highlighting miR‐106b whose overexpression can determine radioresistance both in vitro and in vivo by inhibiting apoptosis and promotion of cell proliferation. The objective of this study was to find the signaling pathways involved with miR‐106b‐mediated radioresistance. CRC gene expression data sets were collected from the public database, The Cancer Genome Atlas (TCGA). In addition, web‐based tools were used to explore TCGA data, specifically that developed by the Memorial Sloan Kettering Cancer Center (MSK) cBioPortal for Cancer Genomics. The public site cBioPortal is hosted at the MSK Molecular Oncology Center, in which the term “colorectal cancer” was searched and 12 studies were selected, creating a single combined study which has 4341 patients and 4488 samples, within which the search for miR‐106b was carried out and the signaling pathways involved with the expression mediated by this miRNA were obtained. The following signaling pathways involved with miR‐106b were obtained: WNT, TP53, TGF‐Beta, RTK‐RAS, PI3K, NRF2, NOTCH, MYC, HIPPO, and its influence on the cell cycle was also noted. miRNAs have been shown to play an important role in the regulation of CRC radio resistance, by controlling various signaling pathways, including cell cycle, proliferation, apoptosis, and DNA damage repair. Furthermore, these results are consistent with recent data that have shown that selective modulation of miRNA activity can improve the response to radiotherapy, providing an innovative antitumor approach based on miRNA‐related gene therapy. Therefore, miRNAs could also serve as targets for the development of new therapeutic strategies to overcome radiation resistance in CRC.

The Critical Role of Dysregulated RhoB Signaling Pathway in Radioresistance of Colorectal Cancer

A novel FOXM1 isoform, FOXM1D, promotes epithelial–mesenchymal transition and metastasis through ROCKs activation in colorectal cancer

RhoB expression associated with chemotherapy response and prognosis in colorectal cancer

The Pathological Significance of Abnormal RON and PD-L1 Expression in Colorectal Cancer

Pathological significance of abnormal recepteur d'origine nantais and programmed death ligand 1 expression in colorectal cancer

Rhoa Regulates Resistance to Irinotecan by Regulating Membrane Transporter and Apoptosis Signaling in Colorectal Cancer

Efficacy of Rigosertib, a Small Molecular RAS Signaling Disrupter for the Treatment of KRAS-mutant Colorectal Cancer

B7-H3 Regulates KIF15-activated ERK1/2 Pathway and Contributes to Radioresistance in Colorectal Cancer.

RIOK1 mediates p53 degradation and radioresistance in colorectal cancer through phosphorylation of G3BP2

Genome-wide RNAi Screening Identifies RFC4 As a Factor That Mediates Radioresistance in Colorectal Cancer by Facilitating Nonhomologous End Joining Repair.

Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair

Deciphering colorectal cancer radioresistance and immune microrenvironment: unraveling the role of EIF5A through single-cell RNA sequencing and machine learning

Signaling Pathways Associated with miR‐106b mediated Radioresistance in the Treatment of Colorectal Cancer

MiR-7-5p/KLF4 Signaling Inhibits Stemness and Radioresistance in Colorectal Cancer.

RAC1 Involves in the Radioresistance by Mediating Epithelial-Mesenchymal Transition in Lung Cancer

Long Non-Coding RNA Influences Radiosensitivity of Colorectal Carcinoma Cell Lines by Regulating Cyclin D1 Expression

RBBP6 Increases Radioresistance and Serves As a Therapeutic Target for Preoperative Radiotherapy in Colorectal Cancer

RhoB Acts As a Tumor Suppressor That Inhibits Malignancy of Clear Cell Renal Cell Carcinoma

Silencing of RHEB Inhibits Cell Proliferation and Promotes Apoptosis in Colorectal Cancer Cells Via Inhibition of the Mtor Signaling Pathway

Baseline MAPK signaling activity confers intrinsic radioresistance to KRAS-mutant colorectal carcinoma cells by rapid upregulation of heterogeneous nuclear ribonucleoprotein K (hnRNP K)

MAPK Signaling-Mediated RFNG Phosphorylation and Nuclear Translocation Restrain Oxaliplatin-Induced Apoptosis and Ferroptosis